Key Highlights

  • Revenue fell 18.6% to USD 10.2 million, below the USD 12.64 million estimate.
  • Gross Margin widened to 42.4% from 32.1%, with Gross Profit up to USD 4.3 million.
  • Net loss was USD 1.4 million, or USD 0.08 per share, versus USD 0.04 estimated.
  • Cash and equivalents were USD 3.7 million at October 3, 2026.

Revenue Declines but Margin Improves

IRIDEX Corporation (NASDAQ:IRIX) reported fiscal third-quarter Revenue of USD 10.2 million, down 18.6% from USD 12.5 million and below the USD 12.64 million estimate. The company said revenue fell across all product groups, citing macroeconomic conditions and customer purchases that had been pulled forward.

Gross profit rose to USD 4.3 million from USD 4.0 million, and gross margin increased to 42.4% from 32.1%. The company credits cost-reduction initiatives for the margin gain, and cost of revenues fell to USD 5.9 million from USD 8.5 million.

Operating Expenses and Net Loss

Total operating expenses were USD 5.5 million, little changed from USD 5.4 million. Sales and Marketing expense decreased USD 0.3 million, or 9.4%, to USD 2.4 million on continued cost control. General and administrative expense rose 13.8% to USD 2.0 million, which the company ties to its corporate office relocation from Mountain View. Research and Development expense was USD 1.0 million, roughly flat.

Loss from operations was USD 1.2 million versus USD 1.4 million. Net loss was USD 1.4 million, or USD 0.08 per share, compared with USD 1.6 million, or USD 0.09 per share, a year earlier, and against an estimated loss of USD 0.04 per share.

Nine-Month Results and Liquidity

For the nine months, revenue was USD 34.5 million versus USD 38.0 million, gross margin was 38.6% versus 36.2%, and net loss narrowed to USD 3.2 million from USD 4.3 million, or USD 0.18 per share versus USD 0.25. Other expense, net, was USD 0.5 million versus USD 1.7 million.

At October 3, 2026, the company held cash and cash equivalents of USD 3.7 million. During the quarter it issued 258,310 common shares in connection with a paydown of accrued interest payable, and it reported 17.6 million weighted average basic and diluted shares, up from 17.0 million a year earlier.

Nine-month detail shows cost of revenues of USD 21.2 million versus USD 24.2 million, gross profit of USD 13.3 million versus USD 13.8 million and operating expenses of USD 15.9 million versus USD 16.3 million. Research and development was USD 2.9 million versus USD 2.7 million, sales and marketing USD 7.5 million versus USD 7.6 million and general and administrative USD 5.5 million versus USD 5.9 million. Loss from operations was USD 2.5 million versus USD 2.6 million, and the provision for income taxes was USD 206,000 versus USD 37,000.

Items Worth Following

IRIDEX describes itself as focused on "sight-threatening eye conditions", including glaucoma and retinal diseases, with MicroPulse and Endpoint Management technologies. The filing points readers to revenue by product group, the durability of the margin gains from cost reductions, Operating Expense levels after the office move and the cash balance as the main reference points for the next report.